 |
|
|
| |
bNAb Sensitivity Does Not Fully Explain Post-Treatment Control in Early HIV–Treated Women During ATI
|
| |
| |
CROI 2026 Feb 22-25 Denver
Lisa Selzer1, Krista Dong2,3,4, Thumbi Ndung'u4,5,6,7, Ross Martin1, Xiaopeng Liu1, Leonid Serebryannyy8, Megha Mehrotra1, Devi SenGupta1, Romas Geleziunas1, Christian Callebaut1, Laurie A VanderVeen1
1Gilead Sciences, Inc., Foster City, CA, USA; 2Harvard Medical School, Cambridge, MA, USA; 3Massachusetts General Hospital, Boston, MA, USA; 4Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; 5HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; 6Africa Health Research Institute, Durban, South Africa; 7Division of Infection and Immunity, University College London, London, UK; 8Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
CROI2025: Evaluation of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With HIV-1 During Analytical Treatment Interruption
|
| |
|
|
|
|
|
